Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588896095> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2588896095 endingPage "vii100" @default.
- W2588896095 startingPage "vii99" @default.
- W2588896095 abstract "Objective: We report on team medical care with molecular targeting drugs for metastatic thyroid cancer. Results: The team involved the departments of breast and endocrine surgery, medical oncology, dermatology, and radiation Oncology, as well as pharmacists and nurses. Sixteen patients (pts) received sorafenib (10) or lenvatinib (10, including 4 switched from sorafenib). There were 6 men and 10 women (median age: 69 years) with differentiated thyroid cancer (15) or Anaplastic carcinoma (1). Sorafenib was started at 800 mg, but was discontinued, reduced, or suspended due to adverse events. Median treatment period was 6.7 months. Maintenance dose was 400 mg in 6 pts treated for > 6 months. Response rate (RR) was 14% in 7 evaluable pts. Major adverse events were hand-and-foot syndrome (HFS) in 70%, malaise in 70%, and hypertension (HT), rash, and anorexia in 50% each. Three pts discontinued due to erythema exsudativum multiforme. There were no treatment-related deaths. Lenvatinib was started at 24 mg. Median treatment period was 2.1 months. In 4 pts treated for > 3 months, the maintenance dose was 20 mg (1), 14 mg (2), or 10 mg (1). RR was 50% in 8 evaluable pts. Major adverse events were HT in 80%, malaise in 70%, anorexia in 70%, HFS in 50%, and diarrhea in 30%. There were 2 treatment-related deaths (bleeding). Conclusions: The cross-departmental team set individual strategies, allowing longer dosing of molecular targeting drugs." @default.
- W2588896095 created "2017-02-24" @default.
- W2588896095 creator A5001837344 @default.
- W2588896095 creator A5013695615 @default.
- W2588896095 creator A5022368171 @default.
- W2588896095 creator A5027783702 @default.
- W2588896095 creator A5038765255 @default.
- W2588896095 creator A5055789061 @default.
- W2588896095 creator A5061842689 @default.
- W2588896095 creator A5072783490 @default.
- W2588896095 creator A5079356546 @default.
- W2588896095 creator A5087322406 @default.
- W2588896095 date "2016-11-01" @default.
- W2588896095 modified "2023-10-18" @default.
- W2588896095 title "Efficacy and safety of molecular targeting drugs in patients with metastatic thyroid cancer" @default.
- W2588896095 doi "https://doi.org/10.1093/annonc/mdw523.027" @default.
- W2588896095 hasPublicationYear "2016" @default.
- W2588896095 type Work @default.
- W2588896095 sameAs 2588896095 @default.
- W2588896095 citedByCount "0" @default.
- W2588896095 crossrefType "journal-article" @default.
- W2588896095 hasAuthorship W2588896095A5001837344 @default.
- W2588896095 hasAuthorship W2588896095A5013695615 @default.
- W2588896095 hasAuthorship W2588896095A5022368171 @default.
- W2588896095 hasAuthorship W2588896095A5027783702 @default.
- W2588896095 hasAuthorship W2588896095A5038765255 @default.
- W2588896095 hasAuthorship W2588896095A5055789061 @default.
- W2588896095 hasAuthorship W2588896095A5061842689 @default.
- W2588896095 hasAuthorship W2588896095A5072783490 @default.
- W2588896095 hasAuthorship W2588896095A5079356546 @default.
- W2588896095 hasAuthorship W2588896095A5087322406 @default.
- W2588896095 hasBestOaLocation W25888960951 @default.
- W2588896095 hasConcept C121608353 @default.
- W2588896095 hasConcept C126322002 @default.
- W2588896095 hasConcept C141071460 @default.
- W2588896095 hasConcept C143998085 @default.
- W2588896095 hasConcept C197934379 @default.
- W2588896095 hasConcept C2776264508 @default.
- W2588896095 hasConcept C2778019345 @default.
- W2588896095 hasConcept C2778570526 @default.
- W2588896095 hasConcept C2778654693 @default.
- W2588896095 hasConcept C2778695046 @default.
- W2588896095 hasConcept C2779277585 @default.
- W2588896095 hasConcept C2779761222 @default.
- W2588896095 hasConcept C2780256643 @default.
- W2588896095 hasConcept C71924100 @default.
- W2588896095 hasConceptScore W2588896095C121608353 @default.
- W2588896095 hasConceptScore W2588896095C126322002 @default.
- W2588896095 hasConceptScore W2588896095C141071460 @default.
- W2588896095 hasConceptScore W2588896095C143998085 @default.
- W2588896095 hasConceptScore W2588896095C197934379 @default.
- W2588896095 hasConceptScore W2588896095C2776264508 @default.
- W2588896095 hasConceptScore W2588896095C2778019345 @default.
- W2588896095 hasConceptScore W2588896095C2778570526 @default.
- W2588896095 hasConceptScore W2588896095C2778654693 @default.
- W2588896095 hasConceptScore W2588896095C2778695046 @default.
- W2588896095 hasConceptScore W2588896095C2779277585 @default.
- W2588896095 hasConceptScore W2588896095C2779761222 @default.
- W2588896095 hasConceptScore W2588896095C2780256643 @default.
- W2588896095 hasConceptScore W2588896095C71924100 @default.
- W2588896095 hasLocation W25888960951 @default.
- W2588896095 hasOpenAccess W2588896095 @default.
- W2588896095 hasPrimaryLocation W25888960951 @default.
- W2588896095 hasRelatedWork W2183602213 @default.
- W2588896095 hasRelatedWork W2291457300 @default.
- W2588896095 hasRelatedWork W2595204361 @default.
- W2588896095 hasRelatedWork W2783251885 @default.
- W2588896095 hasRelatedWork W2788162170 @default.
- W2588896095 hasRelatedWork W2964847999 @default.
- W2588896095 hasRelatedWork W2966674226 @default.
- W2588896095 hasRelatedWork W3093021181 @default.
- W2588896095 hasRelatedWork W3183971356 @default.
- W2588896095 hasRelatedWork W4315485237 @default.
- W2588896095 hasVolume "27" @default.
- W2588896095 isParatext "false" @default.
- W2588896095 isRetracted "false" @default.
- W2588896095 magId "2588896095" @default.
- W2588896095 workType "article" @default.